Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines

Vaccine

Volumn 29, Issue 18, 2011, Pages 3476-3482

  Park, H J ^a   Qin, H ^a   Cha, S C ^a   Sharma, R ^a   Chung, Y ^a   Schluns, K S ^a   Neelapu, S S ^a   Overwijk, W W ^a   Hwu, P ^a   Kwak, L W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer vaccine; Defensin beta 2 (mBD2); TLR4

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 2 MELANOMA GP100 FUSION PROTEIN; BETA DEFENSIN 2 OVALBUMIN FUSION PROTEIN; CANCER VACCINE; CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS PRESENTATION; DENDRITIC CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR RESISTANCE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; BETA-DEFENSINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; GP100 MELANOMA ANTIGEN; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; RECEPTORS, CCR6; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 79955026559     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.061     Document Type: Article

References (36)

1. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3(August (8)):630-641.
2. Overwijk W.W. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 2005, 17(April (2)):187-194.
3. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007, 27(November (5)):687-690.
4. Stevenson F.K., Rice J., Ottensmeier C.H., Thirdborough S.M., Zhu D. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 2004, 199(June):156-180.
5. Biragyn A., Tani K., Grimm M.C., Weeks S., Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999, 17(March (3)):253-258.
6. Biragyn A., Surenhu M., Yang D., Ruffini P.A., Haines B.A., Klyushnenkova E., et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001, 167(December (11)):6644-6653.
7. Biragyn A., Belyakov I.M., Chow Y.H., Dimitrov D.S., Berzofsky J.A., Kwak L.W. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002, 100(August (4)):1153-1159.
8. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298(November (5595)):1025-1029.
9. Ruffini P.A., Biragyn A., Coscia M., Harvey L.K., Cha S.C., Bogen B., et al. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol 2004, 76(July (1)):77-85.
10. Biragyn A., Ruffini P.A., Coscia M., Harvey L.K., Neelapu S.S., Baskar S., et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 2004, 104(October (7)):1961-1969.
11. Schiavo R., Baatar D., Olkhanud P., Indig F.E., Restifo N., Taub D., et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006, 107(June (12)):4597-4605.
12. Biragyn A., Schiavo R., Olkhanud P., Sumitomo K., King A., McCain M., et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity. J Immunol 2007, 179(July (2)):1381-1388.
13. Qin H., Cha S.C., Neelapu S.S., Liu C., Wang Y.H., Wei J., et al. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Vaccine 2010, 28(November (50)):7970-7978.
14. Till B.G., Jensen M.C., Wang J., Chen E.Y., Wood B.L., Greisman H.A., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112(September (6)):2261-2271.
15. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adaptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002, 99(December (25)):16168-16173.
16. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(October (5796)):126-129.
17. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12(October (20 Pt 1)):6106-6115.
18. Laport G.G., Levine B.L., Stadtmauer E.A., Schuster S.J., Luger S.M., Grupp S., et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003, 102(September (6)):2004-2013.
19. Kim S.K., Schluns K.S., Lefrancois L. Induction and visualization of mucosal memory CD8 T cells following systemic virus infection. J Immunol 1999, 163(October (8)):4125-4132.
20. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31(November (5)):787-798.
21. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198(August (4)):569-580.
22. Overwijk W.W., Restifo N.P. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001, (May). [Chapter 20, Unit 20 1].
23. Liu C., Lou Y., Lizee G., Qin H., Liu S., Rabinovich B., et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008, 118(March (3)):1165-1175.
24. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002, 2(April (4)):227-238.
25. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974.
26. Qin H., Cha S.C., Neelapu S.S., Lou Y., Wei J., Liu Y.J., et al. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 2009, 114(November (19)):4142-4149.
27. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(July (7)):505-517.
28. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154(April (8)):3961-3968.
29. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A 0201-binding residues. J Immunol 1996, 157(September (6)):2539-2548.
30. Overwijk W.W., Tsung A., Irvine K.R., Parkhurst M.R., Goletz T.J., Tsung K., et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of " self" -reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998, 188(July (2)):277-286.
31. Schreurs M.W., de Boer A.J., Figdor C.G., Adema G.J. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 1998, 58(June (12)):2509-2514.
32. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61(September (17)):6451-6458.
33. Yang D., Chertov O., Bykovskaia S.N., Chen Q., Buffo M.J., Shogan J., et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286(October (5439)):525-528.
34. Burgdorf S., Scholz C., Kautz A., Tampe R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008, 9(May (5)):558-566.
35. Chen M., Barnfield C., Naslund T.I., Fleeton M.N., Liljestrom P. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol 2005, 79(March (5)):2964-2972.
36. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(October (5594)):850-854.